Cabaletta Bio (CABA) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CABA Stock Alerts $13.32 -0.02 (-0.15%) (As of 04/22/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePhilly-area biotech is worried about Congress’ crackdown on Chinese manufacturersmsn.com - April 18 at 7:43 PMCabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Buy" by Analystsamericanbankingnews.com - April 18 at 2:16 AMCabaletta Bio (NASDAQ:CABA) Stock Price Down 4.2%marketbeat.com - April 17 at 1:52 PM🛠️ One Philly rowhouse at a time | Morning Newslettermsn.com - April 17 at 9:15 AMCabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 19.9% in Marchmarketbeat.com - April 13 at 9:36 PMCabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by Vanguard Group Inc.marketbeat.com - April 12 at 4:09 AMCabaletta Bio (NASDAQ:CABA) Stock Price Up 5% Following Analyst Upgrademarketbeat.com - April 5 at 10:44 AMCabaletta Bio's (CABA) Overweight Rating Reiterated at Cantor Fitzgeraldmarketbeat.com - April 5 at 10:27 AMCabaletta Bio (NASDAQ:CABA) Given New $30.00 Price Target at Citigroupmarketbeat.com - April 4 at 12:45 PMWellington Management Group LLP Makes New Investment in Cabaletta Bio, Inc. (NASDAQ:CABA)marketbeat.com - March 27 at 4:09 AMStifel lifts Cabaletta Bio target to $32 on myositis positioninvesting.com - March 23 at 12:18 PMCabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runwayfinance.yahoo.com - March 23 at 7:17 AMStrong Buy on Cabaletta Bio: Promising CAR T Candidate and Robust Financial Outlookmarkets.businessinsider.com - March 22 at 4:15 PMCabaletta Bio's (CABA) "Overweight" Rating Reiterated at Cantor Fitzgeraldmarketbeat.com - March 22 at 2:58 PMCabaletta Bio Earns ‘Buy’ Rating on Impressive Clinical Progress and Strategic Market Positioningmarkets.businessinsider.com - March 21 at 7:24 PMCABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023investorplace.com - March 21 at 2:05 PMCabaletta gets FDA orphan drug status for systemic sclerosis drugmsn.com - March 21 at 7:10 AMCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinance.yahoo.com - March 21 at 7:10 AMCabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 21 at 7:00 AMCabaletta Bio Says FDA Grants Orphan Drug Designation To CABA-201 To Treat Systemic Sclerosismarkets.businessinsider.com - March 20 at 4:09 PMCabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosisfinance.yahoo.com - March 20 at 4:09 PMCabaletta Bio Target of Unusually Large Options Trading (NASDAQ:CABA)marketbeat.com - March 19 at 1:15 PMA major cog in Philly biotech is in congressional crosshairs for its Chinese ownershipmsn.com - March 19 at 5:36 AMCabaletta Bio (NASDAQ:CABA) Shares Down 6.4% marketbeat.com - March 18 at 12:43 PMCabaletta Bio (CABA) to Release Quarterly Earnings on Thursdaymarketbeat.com - March 13 at 7:39 AMCabaletta Bio (NASDAQ:CABA) Trading Down 4.5%marketbeat.com - March 11 at 12:45 PMCabaletta Bio Set to Ignite Conversation at Upcoming Health Care Conferencesmsn.com - March 5 at 6:41 AMCabaletta Bio, Inc. (NASDAQ:CABA) Shares Purchased by Citigroup Inc.marketbeat.com - March 2 at 4:38 AMSwiss National Bank Invests $930,000 in Cabaletta Bio, Inc. (NASDAQ:CABA)marketbeat.com - March 1 at 4:04 AMCabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of "Buy" from Analystsmarketbeat.com - February 28 at 1:19 AMSeveral Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4finance.yahoo.com - February 27 at 2:19 PMCabaletta Bio to Participate in Upcoming Investor Conferences in Marchglobenewswire.com - February 27 at 8:00 AMRafferty Asset Management LLC Takes $1.80 Million Position in Cabaletta Bio, Inc. (NASDAQ:CABA)marketbeat.com - February 23 at 5:47 AMCabaletta Bio Stock (NASDAQ:CABA) Dividends: History, Yield and Datesbenzinga.com - February 21 at 10:05 PMCabaletta Bio, Inc. (NASDAQ:CABA) Shares Purchased by Barclays PLCmarketbeat.com - February 21 at 4:13 AMCABA Mar 2024 35.000 callfinance.yahoo.com - February 17 at 1:12 PMCABA Mar 2024 30.000 callfinance.yahoo.com - February 17 at 8:12 AMCabaletta Bio (NASDAQ:CABA) Shares Gap Up to $22.03marketbeat.com - February 5 at 11:54 AMStrong Buy Rating for Cabaletta Bio Amid Positive CART Therapy Prospects and Market Potentialmarkets.businessinsider.com - February 5 at 8:43 AMCabaletta Bio (NASDAQ:CABA) Coverage Initiated at Jefferies Financial Groupmarketbeat.com - February 5 at 7:21 AMFDA Awards Orphan Drug Designation to Cabaletta's Innovative Myositis Therapymsn.com - February 3 at 7:08 AMCabaletta Bio (NASDAQ:CABA) Shares Up 6.1%marketbeat.com - February 2 at 1:59 PMCabaletta Bio CEO to Speak at Guggenheim's 6th Annual Biotech Conferencemsn.com - February 2 at 10:14 AMCabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatmentmarketwatch.com - February 1 at 6:55 PMCabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forwardseekingalpha.com - January 31 at 9:41 AMCabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conferencefinance.yahoo.com - January 31 at 9:41 AMInsider Selling: Cabaletta Bio, Inc. (NASDAQ:CABA) Insider Sells 11,000 Shares of Stockmarketbeat.com - January 19 at 9:19 PMJennison Associates LLC Increases Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)marketbeat.com - January 18 at 6:37 AMAre Investors Undervaluing Cabaletta Bio, Inc. (NASDAQ:CABA) By 47%?finance.yahoo.com - January 9 at 7:40 AMCabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Rating of "Buy" from Brokeragesmarketbeat.com - January 9 at 2:19 AM Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media. Simply tap here now to subscribe and start getting "Insider Financial Advantage" CABA Media Mentions By Week CABA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CABA News Sentiment▼0.270.46▲Average Medical News Sentiment CABA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CABA Articles This Week▼42▲CABA Articles Average Week Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CRGX News Today CGEM News Today OPK News Today RGNX News Today IMTX News Today RLAY News Today HLVX News Today PRME News Today PROK News Today BCRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CABA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
